VIRAMUNE (Nevirapine)

This chapter provides basic characteristics, FDA-approved indications, side effects/toxicity, dosage information, drug/food interactions and antimicrobial therapy art of VIRAMUNE (nevirapine). Nevirapine inhibits reverse transcriptase activity by binding the enzyme. It is indicated for treatment of HIV-1 in combinations with other antiretroviral agents. Nevirapine causes hepatic enzyme induction of CYP3A4; coadministration of nevirapine with drugs primarily metabolized by 3A4 and 2B6 isozymes may result in altered plasma concentrations of the coadministered drug. Drugs that induce CYP3A4 activity would be expected to increase the clearance of nevirapine, resulting in lowered plasma concentrations. Nevirapine is administered in 200 mg tablets and a white oral suspension containing 50 mg nevirapine in each 5 mL. The recommended dose for nevirapine is one 200 mg tablet daily for the first 14 days, followed by one 200 mg tablet twice daily, in combination with other antiretroviral agents.